Despite recent advances in tissue engineering and regenerative medicine, ischemia related to cardiovascular disease results in the death of more than 100,000 amputations per year from peripheral artery disease (PAD) in the US alone. Very few biomaterials have been examined and of those examined (e.g. fibrin, collagen, alginate, and Matrigel). None of these provide all the native components of the skeletal muscle extracellular matrix. Most are limited to improving growth factor and cell delivery.
Currently no material meets all of the properties of an ideal scaffold, namely enhanced neovascularization to reduce the ischemic environment, better cell adhesion, survival, and maturation of endogenous or exogenously added cells. There is a need to develop improved compositions for minimally invasive tissue-engineered therapies for the treatment of critical limb ischemia.
Researchers at the University of California, San Diego have patented tissue specific de-cellularized matrices for treating peripheral artery disease, critical limb ischemia, and have potential for skeletal muscle tissue engineering. Mammalian extracellular matrix provides scaffolds for cell growth, recruitment and replacement as well as a biocompatible material that can be used to deliver drugs to specific tissues (e.g. skeletal myoblasts, stem cells, and other cell types relevant to skeletal muscle repair).
UC San Diego is seeking companies to commercially develop this patented technology into products. US patent rights are available for licensing.
|United States Of America||Issued Patent||10,251,977||04/09/2019||2012-053|
|United States Of America||Issued Patent||9,592,256||03/14/2017||2012-053|